AAPM Methadone Education Curriculum - CME

FREE ENDURING INTERNET ACTIVITY

Release date: August 27, 2015
Valid through: August 27, 2018

Format: Video, Didactic, PowerPoint

Overview:
With a commitment to making high-impact, long-term change, the American Academy of Pain Medicine (AAPM) has developed a patient safety-focused web-based continuing medical education (CME) program for all prescribers of opioids, with a targeted focus on those who prescribe methadone for the treatment of chronic pain. The AAPM’s Methadone Education Curriculum is designed to equip prescribers with the knowledge, skills, and behaviors they need to implement evidence-based safe prescribing practices. Changes in prescribers’ knowledge, competence and performance will minimize risks and reduce harm for patients being treated for chronic pain with methadone.

Goals of the Curriculum:
Improve prescriber knowledge of methadone
Implement risk reduction strategies and patient safety practices in prescribing methadone in both inpatient and outpatient settings
Improve prescriber/patient interactions and patient adherence to proper use of methadone
Improve patient safety and patient outcomes

Faculty:
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA Health Sciences
Salt Lake City, UT



Continuing Education:
The American Academy of Pain Medicine (AAPM) provides an enduring educational program titled Methadone Education Curriculum and offers continuing medical education (CME) for physicians. Successful completion requires that participants view the program, and complete an online post-test and evaluation. Participants receive their CME certificates after they submit their evaluations online.

Accreditation:
The American Academy of Pain Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
The American Academy of Pain Medicine designates this enduring internet activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding:
Funding for the Methadone Education Curriculum was made possible by a grant from the American Academy of Pain Medicine Foundation (AAPMF).

Disclaimer:
The material presented in this activity represents the opinion of the authors/faculty and not necessarily the view of the American Academy of Pain Medicine.

Faculty/Planner Disclosures & Policy:
It is the policy of AAPM to plan and implement educational activities in accordance with ACCME’s Essential Areas and Elements to ensure balance, independence, objectivity, and scientific rigor. All program faculty and planners are required to disclose all financial relationships they may have or have had within the last 12 months with commercial interests whose products or services are related to the subject matter of the presentation. Any real or apparent conflicts of interest will be resolved prior to the presentation. All confirmed faculty disclosure information will be made available to participants prior to the activity. Faculty will also be expected to disclose this information to the audience both verbally and in print (slide presentation) at the beginning of each presentation. Faculty members are also required to inform program participants if any unlabeled uses of products regulated by the U.S. Food and Drug Administration will be discussed.

Disclosure information appears below.

Planners:
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA International
Salt Lake City, UT
Acura Pharmaceuticals (honorarium—consultant/travel expenses);
AstraZeneca (honorarium—consultant/travel expenses);
BioDelivery Sciences International (honorarium—consultant/travel expenses);
Bristol-Myers Squibb (BMS) (travel expenses);
CVS Caremark (honorarium—consultant);
Depomed (honorarium—advisory board/travel expenses);
Egalet (honorarium—advisory board);
Grunenthal USA (honorarium—consultant/travel expenses);
Inspirion Pharmaceuticals (honorarium—advisory board/travel expenses);
Insys Therapeutics (honorarium—advisory board/travel expenses);
Jazz Pharmaceuticals (travel expenses);
Kaleo (honorarium—advisory board/travel expenses);
Mallinckrodt Pharmaceuticals (honorarium—consultant/honorarium—advisory board/travel expenses);
Nektar Therapeutics (travel expenses);
Nevro Corporation (honorarium—consultant/travel expenses);
Orexo Pharmaceuticals (travel expenses);
Signature Therapeutics (honorarium—advisory board);
Synchrony Healthcare (honorarium—consultant);
Teva Pharmaceuticals (honorarium—advisory board/travel expenses)
Travena (honorarium—advisory board/travel expenses)


Jennifer Westlund, MSW
Director of Education
American Academy of Pain Medicine
No relevant financial relationships

Angela Casey
VP, Medical Director
PharmaCom Group
No relevant financial relationships

Faculty:
Lynn R. Webster, MD
Vice President of Scientific Affairs
PRA International
Salt Lake City, UT
Acura Pharmaceuticals (honorarium—consultant/travel expenses);
AstraZeneca (honorarium—consultant/travel expenses);
BioDelivery Sciences International (honorarium—consultant/travel expenses);
Bristol-Myers Squibb (BMS) (travel expenses);
CVS Caremark (honorarium—consultant);
Depomed (honorarium—advisory board/travel expenses);
Egalet (honorarium—advisory board);
Grunenthal USA (honorarium—consultant/travel expenses);
Inspirion Pharmaceuticals (honorarium—advisory board/travel expenses);
Insys Therapeutics (honorarium—advisory board/travel expenses);
Jazz Pharmaceuticals (travel expenses);
Kaleo (honorarium—advisory board/travel expenses);
Mallinckrodt Pharmaceuticals (honorarium—consultant/honorarium—advisory board/travel expenses);
Nektar Therapeutics (travel expenses);
Nevro Corporation (honorarium—consultant/travel expenses);
Orexo Pharmaceuticals (travel expenses);
Signature Therapeutics (honorarium—advisory board);
Synchrony Healthcare (honorarium—consultant);
Teva Pharmaceuticals (honorarium—advisory board/travel expenses)
Travena (honorarium—advisory board/travel expenses)

Disclosure Disclaimer:
Please note: The disclosure information stated above were relevant financial relationships based upon the 12-month reporting period prior to producing this program on April 20, 2015.

Target Audience/Program Overview:
With a commitment to making high-impact, long-term change, the American Academy of Pain Medicine (AAPM) has developed a patient safety-focused Web based continuing medical education (CME) program for all prescribers of opioids, with a targeted focus on those who prescribe methadone for the treatment of chronic pain. The AAPM’s Methadone Education Curriculum is designed to equip prescribers with the knowledge, skills, and behaviors they need to implement evidence-based safe prescribing practices. Changes in prescribers’ knowledge, competence and performance will minimize risks and reduce harm for patients being treated for chronic pain with methadone.

Expert Educational Design:
This education initiative was planned and facilitated by leaders from the American Academy of Pain Medicine (AAPM). AAPM is the leading medical association representing physicians committed to advancing the emerging science and practice of pain medicine. This comprehensive pain medicine curriculum is designed to improve access to quality, evidenced- based multidisciplinary pain care across the healthcare continuum.

Educational Objectives for the Methadone Education Curriculum are as follows:
Module 1: Scope of the Problem and Identification of Key Risk Factors
  1. Evaluate how methadone’s pharmacokinetic and pharmacodynamic mechanisms affect the safety of its use for chronic pain
  2. Describe patient risk factors and prescriber practices that affect the safety of methadone use for chronic pain

Module 2: Improving Patient Safety: Assessment, Management, and Monitoring Practices
  1. Describe key risk factors and perform appropriate assessments to prevent sentinel events from methadone
  2. Communicate with patient and key family members to assess risk and improve patient safety when prescribing methadone
  3. Implement an appropriate risk stratification plan

Module 3: Overdose Prevention and Improving Patient Compliance
  1. Describe 8 opioid safety principles for patients and caregivers
  2. Identify signs of opioid overdose and relate these to patients and caregivers
  3. Identify candidates for a prescription of the opioid antagonist naloxone

Module 4: Case Studies: Improving Clinical Decision Making and Patient Safety/Outcomes
Devise a plan to implement the Methadone for Pain Management: AAPM Recommended Practices:
  1. Document the initiation of methadone therapy at 15 mg or less per day in 3 or 4 divided doses
  2. Document the increase of methadone dose at 10 mg or less no more often than once per week
  3. Document the assessment for prolonged QT with doses >100 mg methadone per day and identify patients at risk based on cardiac history and concurrent medication use
  4. Evaluate for sleep apnea in at-risk patients and those exceeding 50 mg methadone per day
  5. Communicate with patient the critical importance of not using more methadone than directed even if the pain is not well controlled
  6. Use immediate-release opioid formulations during methadone dose titrations if the initial dose of methadone is inadequate to manage the pain

Provider:
Presented by the American Academy of Pain Medicine in partnership with PharmaCom Group, Inc. and hosted by Blue Sky Broadcast. The AAPM Methadone Curriculum was filmed on location at Studio B, Lone Peak Productions, Salt Lake City, Utah.